Table II.
miRs significantly differentially expressed (P<0.01) in medulloblastoma tissue compared with normal control samples.
| Gene names | Log fold change |
|---|---|
| Upregulated miRs | |
| hsa-miR-217 | 5.40 |
| hsa-miR-301 | 2.54 |
| hsa-miR-216 | 4.67 |
| hsa-miR-19a | 2.11 |
| hsa-miR-15b | 1.16 |
| hsa-miR-106b | 1.19 |
| hsa-miR-18a | 2.37 |
| hsa-miR-130b | 1.56 |
| hsa-miR-182 | 3.52 |
| hsa-miR-345 | 1.62 |
| hsa-miR-17-3p | 2.10 |
| hsa-miR-96 | 3.71 |
| hsa-miR-582 | 2.06 |
| hsa-miR-622 | 2.57 |
| hsa-miR-532 | 1.12 |
| hsa-miR-19b | 1.02 |
| hsa-miR-18b | 2.31 |
| hsa-miR-632 | 2.52 |
| hsa-miR-148a | 1.13 |
| hsa-miR-17-5p | 2.99 |
| hsa-miR-183 | 3.73 |
| hsa-miR-135a | 1.19 |
| Downregulated miRs | |
| hsa-miR-383 | −3.05 |
| hsa-miR-128a | −2.53 |
| hsa-miR-433 | −2.38 |
| hsa-miR-488 | −2.22 |
| hsa-miR-584 | −2.97 |
| hsa-miR-128b | −2.92 |
| hsa-miR-485-3p | −1.89 |
| hsa-miR-329 | −2.43 |
| hsa-miR-299-5p | −2.22 |
| hsa-miR-133b | −1.60 |
| hsa-miR-330 | −2.37 |
| hsa-miR-181b | −1.17 |
| hsa-miR-138 | −2.03 |
| hsa-miR-770-5p | −2.03 |
| hsa-miR-149 | −1.57 |
| hsa-miR-133a | −1.00 |
| hsa-miR-328 | −1.44 |
| hsa-miR-409-3p | −1.63 |
| hsa-miR-656 | −2.17 |
| hsa-miR-642 | −2.37 |
| hsa-miR-432 | −1.15 |
| hsa-miR-539 | −1.03 |
| hsa-miR-668 | −1.79 |
| hsa-miR-487b | −1.48 |
| hsa-miR-154* | −1.15 |
| hsa-miR-212 | −1.81 |
miR, microRNA. hsa-miR-154*, The precursor miRNA (pre-miRNA) undergoes another endonucleolytic cleavage, which is catalysed by Dicer, generating a miRNA-miRNA* duplex (where miRNA is the antisense, or guide, strand and miRNA* is the sense, or passenger, strand) of approx21-25 nucleotides (38).